Before starting any GLP-1 therapy, its important to discuss: With professional guidance, patients can choose the medication best aligned with their health goals, lifestyle, and safety considerations
Any estimated increase in relative risk must be interpreted in the context of the low overall incidence of NAION
Some peptides (notably GLP-1 receptor agonists like semaglutide and newer dual agonists such as tirzepatide) reduce appetite, slow gastric emptying, and improve blood sugar control- mechanisms that reliably produce weight loss in clinical trials
Combined with topiramate (as Qsymia), results improve to 8-10% average weight loss
Semaglutide starts work by simulating GLP-1 hormone, increasing secretion of insulin, inhibiting glucagon release, overpowering appetite, gastric activity also slow down and leading to better glucose control and weight loss